专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

CA2818548A1 NEUTRALIZING ANTI-CCL20 ANTIBODIES 未知
公开(公告)号：CA2818548A1
公开(公告)日：2012-05-24
申请号：CA2818548
申请日：2011-11-18
申请人： IMAI TOSHIO , KLINE JAMES BRADFORD , KAWANO TETSU , GRASSO LUIGI , SAKAMOTO YOSHIMASA , SPIDEL JARED , NISHIMURA MIYUKI , MURAMOTO KENZO , HORIZOE TATSUO
发明人： IMAI TOSHIO , KLINE JAMES BRADFORD , KAWANO TETSU , GRASSO LUIGI , SAKAMOTO YOSHIMASA , SPIDEL JARED , NISHIMURA MIYUKI , MURAMOTO KENZO , HORIZOE TATSUO
IPC分类号： C12N15/13 , A61K39/395 , C07K16/24 , C07K16/46 , C12N15/63 , C12P21/08
摘要： The disclosure provides humanized, chimeric and murine antibodies that specificity bind to the human CC chemokine ligand 20 (CCL20). The disclosure further provides heavy chains and light chains of the antibodies, as well as isolated nucleic acids, recombinant vectors and host cells that comprise a sequence encoding a heavy chain and/or light chain of the antibodies. Further disclosed are methods of using the anti-CCL20 antibodies for treating disorders including inflammatory and autoimmune disorders as well as cancers.

2. 发明专利

CO6761352A2 Anticuerpos neutralizadores anti-ccl20 未知
公开(公告)号：CO6761352A2
公开(公告)日：2013-09-30
申请号：CO13145744
申请日：2013-06-19
申请人： IMAI TOSHIO , KLINE JAMES BRADFORD , KAWANO TETSU , GRASSO LUIGI , SAKAMOTO YOSHIMASA , SPIDEL JARED , NISHIMURA MIYUKI , MURAMOTO KENZO , HORIZOE TATSUO
发明人： IMAI TOSHIO , KLINE JAMES BRADFORD , KAWANO TETSU , GRASSO LUIGI , SAKAMOTO YOSHIMASA , SPIDEL JARED , NISHIMURA MIYUKI , MURAMOTO KENZO , HORIZOE TATSUO
IPC分类号： C07K16/00
摘要： Nuevos anticuerpos humanizados, quiméricos y murinos que presentan especificidad de unión por el ligando de la quimioquina humana CC 20 (CCL2O). Cadenas pesadas y cadenas livianas de dichos anticuerpos. Ácidos nucleicos aislados, vectores recombinantes y células huésped que comprenden una secuencia que codifica una cadena pesada y/o una cadena liviana de dichos anticuerpos. Método para preparar dichos anticuerpos. Los anticuerpos anti-CCL2O de la invención pueden usarse en aplicaciones terapéuticas, por ejemplo, para tratar los trastornos inflamatorios y autoinmunes y el cáncer.

3. 发明专利

ZA201303571B NEUTRALIZING ANTI-CCL20 ANTIBODIES 未知
公开(公告)号：ZA201303571B
公开(公告)日：2014-12-23
申请号：ZA201303571
申请日：2013-05-16
申请人： IMAI TOSHIO , KLINE JAMES BRADFORD , KAWANO TETSU , GRASSO LUIGI , SAKAMOTO YOSHIMASA , SPIDEL JARED , NISHIMURA MIYUKI , MURAMOTO KENZO , HORIZOE TATSUO
发明人： IMAI TOSHIO , KLINE JAMES BRADFORD , KAWANO TETSU , GRASSO LUIGI , SAKAMOTO YOSHIMASA , SPIDEL JARED , NISHIMURA MIYUKI , MURAMOTO KENZO , HORIZOE TATSUO
IPC分类号： A61K20060101 , C07H20060101 , C07K20060101
摘要： The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.

4. 发明专利

AU2011329647B2 Neutralizing anti-CCL20 antibodies 未知
公开(公告)号：AU2011329647B2
公开(公告)日：2015-10-22
申请号：AU2011329647
申请日：2011-11-18
申请人： GRASSO LUIGI , HORIZOE TATSUO , IMAI TOSHIO , KAWANO TETSU , KLINE JAMES BRADFORD , MURAMOTO KENZO , NISHIMURA MIYUKI , SAKAMOTO YOSHIMASA , SPIDEL JARED
发明人： IMAI TOSHIO , KLINE JAMES BRADFORD , KAWANO TETSU , GRASSO LUIGI , SAKAMOTO YOSHIMASA , SPIDEL JARED , NISHIMURA MIYUKI , MURAMOTO KENZO , HORIZOE TATSUO
IPC分类号： C07K16/00 , A61K39/395 , A61P19/02 , A61P19/10 , A61P29/00 , A61P31/20 , A61P35/00 , C07H21/04 , C07K16/18 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/071 , C12N5/10 , C12N15/13 , C12N15/63 , C12P21/08
摘要： The disclosure provides humanized, chimeric and murine antibodies that specificity bind to the human CC chemokine ligand 20 (CCL20). The disclosure further provides heavy chains and light chains of the antibodies, as well as isolated nucleic acids, recombinant vectors and host cells that comprise a sequence encoding a heavy chain and/or light chain of the antibodies. Further disclosed are methods of using the anti-CCL20 antibodies for treating disorders including inflammatory and autoimmune disorders as well as cancers.

5. 发明专利

MA34738B1 NEUTRALISATION D'ANTICORPS ANTI-CCL20 未知
公开(公告)号：MA34738B1
公开(公告)日：2013-12-03
申请号：MA36013
申请日：2013-06-14
申请人： HORIZOE TASTUO , IMAI TOSHIO , KLINE JAMES BRADFORD , KAWANO TETSU , GRASSO LUIGI , SAKAMOTO YOSHIMASA , SPIDEL JARED , NISHIMURA MIYUKI , MURAMOTO KENZO
发明人： IMAI TOSHIO , KLINE JAMES BRADFORD , KAWANO TETSU , GRASSO LUIGI , SAKAMOTO YOSHIMASA , SPIDEL JARED , NISHIMURA MIYUKI , MURAMOTO KENZO , HORIZOE TATSUO
IPC分类号： C07K16/00 , A61K39/395 , C07H21/04
摘要： La présente invention concerne de nouveaux anticorps humanisés, chimères et murins ayant une spécificité de liaison au ligand 20 de la chimiokine CC humaine (CCL20). La présente invention concerne en outre des chaînes lourdes et des chaînes légères desdits anticorps. L'invention concerne également des acides nucléiques isolés, des vecteurs recombinants et des cellules hôtes comprenant une séquence codant pour une chaîne lourde et/ou une chaîne légère desdits anticorps, et un procédé de préparation desdits anticorps. Les anticorps anti-CCL20 de l'invention peuvent être utilisés dans des applications thérapeutiques destinées à traiter, par exemple, des troubles inflammatoires et autoimmuns et le cancer.

6. 发明申请

WO0102400A8 FUSED IMIDAZOLE COMPOUNDS AND REMEDIES FOR DIABETES MELLITUS 审中-公开
标题翻译：熔化的咪唑化合物和糖尿病患者的补救措施
公开(公告)号：WO0102400A8
公开(公告)日：2001-04-05
申请号：PCT/JP0004358
申请日：2000-06-30
申请人： EISAI CO LTD , ASANO OSAMU , HARADA HITOSHI , YOSHIKAWA SEIJI , WATANABE NOBUHISA , INOUE TAKASHI , HORIZOE TATSUO , YASUDA NOBUYUKI , OHASHI KAYA , MINAMI HIROE , NAGAOKA JUNSAKU , MURAKAMI MANABU , KOBAYASHI SEIICHI , TANAKA ISAO , KAWATA TSUTOMU , SHIMOMURA NAOYUKI , AKAMATSU HIROFUMI , OZEKI NAOKI , SHIMIZU TOSHIKAZU , HAYASHI KENJI , HAGA TOYOKAZU , NEGI SHIGETO , NAITO TOSHIHIKO
发明人： ASANO OSAMU , HARADA HITOSHI , YOSHIKAWA SEIJI , WATANABE NOBUHISA , INOUE TAKASHI , HORIZOE TATSUO , YASUDA NOBUYUKI , OOHASHI KAYA , MINAMI HIROE , NAGAOKA JUNSAKU , MURAKAMI MANABU , KOBAYASHI SEIICHI , TANAKA ISAO , KAWATA TSUTOMU , SHIMOMURA NAOYUKI , AKAMATSU HIROFUMI , OZEKI NAOKI , SHIMIZU TOSHIKAZU , HAYASHI KENJI , HAGA TOYOKAZU , NEGI SHIGETO , NAITO TOSHIHIKO
IPC分类号： A61P3/10 , A61P43/00 , C07D471/04 , C07D473/00 , C07D473/34 , C07D473/40 , A61K31/437 , A61K31/52 , A61K31/522 , C07D213/73 , C07D213/75 , C07D235/18 , C07D239/48 , C07D471/08 , C07D473/18 , C07D487/04
CPC分类号： C07D471/04 , C07D473/00 , C07D473/34 , C07D473/40
摘要： Novel fused imidazole compounds of general formula (I), pharmacologically acceptable salts thereof, or hydrates of both, exhibiting adenosine A2 receptor antagonism and being effective in the prevention and treatment of diabetes mellitus and complications of diabetes; wherein R is optionally alkylated amino or the like; R is hydrogen, alkyl, or the like; R is optionally substituted aryl, a pyridinone group, a pyrimidinone group, or the like; Ar is an optionally sybstituted aryl or heteroaryl group, or the like; and Q and W are each independently N or CH.
摘要翻译：通式（I）的新型稠合咪唑化合物，其药理学上可接受的盐或两者的水合物，显示出腺苷A2受体拮抗作用，并且有效预防和治疗糖尿病以及糖尿病并发症; 其中R 1任选地是烷基化的氨基等; R 2是氢，烷基等; R 3是任选取代的芳基，吡啶酮基，嘧啶酮基等; Ar是任选取代的芳基或杂芳基等; Q和W各自独立地为N或CH。

7. 发明申请

WO2004082715A8 CONCOMITANT DRUG AS THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE 审中-公开
标题翻译：作为治疗诱发剂的治疗药物的可持续药物
公开(公告)号：WO2004082715A8
公开(公告)日：2005-05-12
申请号：PCT/JP2004003662
申请日：2004-03-18
申请人： EISAI CO LTD , HORIZOE TATSUO
发明人： HORIZOE TATSUO
IPC分类号： A61K31/00 , A61K38/13 , A61K45/06 , A61P1/04 , C07K16/24 , A61K45/00
CPC分类号： C07K16/241 , A61K31/00 , A61K38/13 , A61K45/06 , A61K2300/00
摘要： A drug having enhanced efficacy against inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. In particular, a therapeutic agent for inflammatory bowel diseases comprising active ingredient (a) consisting of at least one compound having inflammation inhibiting activity selected from the group consisting of an aminosalicylic acid derivative, an antiinflammatory glucocorticoid, an immunosuppressive compound, an anti-TNFalpha antibody, a neurohypophysial hormone and an antiinfective compound, combined with active ingredient (b) consisting of at least one compound having PPARgamma agonist activity. In the application of this therapeutic agent for inflammatory bowel diseases, compound (a) and compound (b) can be administered simultaneously, separately or with intervals.
摘要翻译：一种具有增强的抗炎症性肠病如溃疡性结肠炎和克罗恩病的功效的药物。特别地，涉及炎症性肠病的治疗剂，其含有由至少一种具有炎症抑制活性的化合物组成的活性成分（a），所述化合物具有选自氨基水杨酸衍生物，抗炎糖皮质激素，免疫抑制化合物，抗TNFα抗体，神经嗜睡激素和抗感染化合物，与由至少一种具有PPARγ激动剂活性的化合物组成的活性成分（b）组合。在该治疗剂用于炎性肠病的应用中，化合物（a）和化合物（b）可以同时，分开地或间隔地施用。

8. 发明专利

IL194188A Triazolone derivative 未知
公开(公告)号：IL194188A
公开(公告)日：2013-08-29
申请号：IL19418808
申请日：2008-09-17
申请人： MATSURA FUMIYOSHI , TAKAO OMAE , EISAI R&D MAN CO LTD , KUSANO KAZUTOMI , CLARK RICHARD , KIRA KAZUNOBU , HIROTA SHINSUKE , AZUMA HIROSHI , NAGAKURA TADASHI , HORIZOE TATSUO , TABATA KIMIYO , INOUE ATSUSHI
发明人： MATSURA FUMIYOSHI , TAKAO OMAE , KUSANO KAZUTOMI , CLARK RICHARD , KIRA KAZUNOBU , HIROTA SHINSUKE , AZUMA HIROSHI , NAGAKURA TADASHI , HORIZOE TATSUO , TABATA KIMIYO , INOUE ATSUSHI
IPC分类号： A61K20060101 , A61P20060101 , C07D20060101
摘要： A Compound represented by the following general formula (1), salts thereof or hydrates of the foregoing is a novel compound useful for treatment and/or prevention of diseases associated with thrombus formation, and which is safer with suitable physicochemical stability. [wherein R 1a , R 1b , R 1c and R 1d each independently represent hydrogen, etc.; R 2 represents optionally substituted phenyl, etc.; R 3 represents optionally substituted C6-10 aryl, etc.; and Z 1 and Z 2 each independently represent hydrogen]

9. 发明专利

MX2013005532A ANTICUERPOS ANTI-LIGANDO DE QUIMIOCINA CC 20 (CCL20) NEUTRALIZANTES. 未知
公开(公告)号：MX2013005532A
公开(公告)日：2013-09-26
申请号：MX2013005532
申请日：2011-11-18
申请人： IMAI TOSHIO
发明人： NISHIMURA MIYUKI , IMAI TOSHIO , GRASSO LUIGI , KLINE JAMES BRADFORD , KAWANO TETSU , SAKAMOTO YOSHIMASA , SPIDEL JARED , MURAMOTO KENSO , HORIZOE TATSUO
IPC分类号： A61K39/395 , C07H21/04 , C07K16/00
摘要： La presente invención se refiere a anticuerpos humanizados, quiméricos y de murino novedosos que tienen especificidad de unión por el ligando de quimiocina CC 20 de humano (CCL20). La presente invención se refiere además a cadenas pesadas y cadenas ligeras de los anticuerpos. La invención también se refiere a ácidos nucleicos aislados, vectores recombinantes y células hospedantes que comprenden una secuencia la cual codifica una cadena pesada y/o una cadena ligera de los anticuerpos y a un método para preparar los anticuerpos. Los anticuerpos anti-CCL20 de la invención se puede utilizar en aplicaciones terapéuticas para tratar, por ejemplo, trastornos inflamatorios y autoinmunes y el cáncer.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式